http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103665044-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e059b4e2268ae09ba48bfce7f3b9b86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_354e132d58215c4d082342a48587f30f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6561 |
| filingDate | 2013-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e47a3697b0aa2f753afe8bceb5198163 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e0aaa376832dae0e237d54cd947d0bd |
| publicationDate | 2015-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103665044-B |
| titleOfInvention | Adefovir dipivoxil compound |
| abstract | The invention relates to the field of pharmacy and in particular relates to an adefovir dipivoxil compound. Adefovir dipivoxil is a crystal; an X-ray powder diffraction pattern measured through Cu-Ka is represented by the figure 10. The purity of the adefovir dipivoxil compound disclosed by the invention can be up to 99.95-99.9 percent. According a crystallization method disclosed by the invention, the solvent content is low, and the adefovir dipivoxil compound is safe and reliable in clinical application. A stability test shows that the adefovir dipivoxil crystal compound disclosed by the invention is high in stability, and a preparation of the adefovir dipivoxil crystal compound is high in dissolution rate. |
| priorityDate | 2013-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.